共 50 条
- [21] POSSIBLE AMENDMENTS TO ORPHAN DRUG-ACT - RETROACTIVITY AND SALES CAP WOULD-BE AVOIDED BIOTECHNOLOGY LAW REPORT, 1994, 13 (04): : 481 - 482
- [22] The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success MILBANK QUARTERLY, 2024, 102 (01): : 83 - 96
- [26] PRESCRIPTION FOR THE ORPHAN DRUG-ACT - THE IMPACT OF THE FDAS 1992 REGULATIONS AND THE LATEST CONGRESSIONAL PROPOSALS FOR REFORM FOOD AND DRUG LAW JOURNAL, 1995, 50 (01): : 125 - 147